Moderna Lifts 2026 Revenue Growth Outlook to 15%–25%

Moderna raised its full-year 2026 revenue growth outlook to 15%–25% in third-quarter results released November 6, 2026, well above the up-to-10% it had previously reiterated. Its GAAP (standard accounting-rule) operating expense outlook improved by about $0.2 billion. Its second-quarter filing expected about 55% of second-half revenue to land in the third quarter.